Advances in Ovarian Cancer Research

Accreditation Statement 
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

Credit Designation Statement
AACR has designated this live activity for a maximum of 18.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming CME Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s) for this live continuing medical education activity must complete the CME Request for Credit Survey by Monday, Oct. 28, 2019. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via a link below, and via email. Your CME certificate will be sent to you via email after the completion of the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 18.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.  

To receive ABIM MOC, participants must request MOC in the CME Request for Credit Survey and complete all questions. Once these steps are completed, AACR will submit your completion information via the ACCME’s Program and Activity Reporting System for the purpose of granting MOC points.

Statement of Educational Need, Target Audience, and Learning Objectives
Approximately 22,530 women will be diagnosed with ovarian cancer this year in the United States. There is no recommended screening test for ovarian cancer; therefore, about 60% of ovarian cancer cases are diagnosed at an advanced stage, resulting in a lower survival rate. In the United States, ovarian cancer is the fifth leading cause of cancer deaths among women, more than any other gynecologic cancer. The overall five-year survival rate is 47%; however, in the instance of early diagnosis of localized disease, the five-year survival rate increases to 92%. These data call on the need for an improvement of early-detection testing and identification of high-risk individuals to diagnose patients at the earliest stage possible and increase the likelihood of treatment success.

The treatment of ovarian cancer has expanded beyond first-line surgery, chemotherapy, and radiation due in large part to continued advancements in areas such as DNA damage/repair, immunology, the tumor microenvironment, and molecular drivers. With advances in these and other areas, it is critical to assess these basic research underpinnings that inform clinical therapeutics, as well as discuss how observations from clinical practice can be back-translated into subsequent basic mechanistic research.

This conference will allow those seeking credit to engage in panel discussions, networking roundtables, and two poster sessions. The scientific presentations and networking opportunities will allow for optimal collaboration between physicians, scientists, and advocates.

After participating in this CME activity, physicians should be able to:

  1. Analyze current basic and translational ovarian cancer research in the fields of genetics, immunology/immunotherapy, and the tumor microenvironment.

  2. Articulate current approaches to assess the resistance and response to therapy.

  3. Identify vulnerabilities in rare ovarian tumor types that can be exploited therapeutically.

  4. Demonstrate knowledge of current advances in the prevention and early detection of ovarian cancer, including risk assessment.

  5. Describe how analyzing exceptional responders to therapy can further advance our understanding of ovarian cancer.

  6. Compare the benefits and limitations of cutting-edge model systems to study the biology of ovarian cancer.

Disclosure Statement
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.

Acknowledgment of Financial or Other Support
This activity is supported by professional educational grants  and will be disclosed at the activity. 

Questions about CME?
Please contact the Office of CME at (215) 440-9300 or

Top of page